The article examines the impact of downstaging after cystectomy on survival outcomes in patients with primary versus secondary muscle-invasive bladder cancer (MIBC). Topics discussed include differences in downstaging rates (<pT2 and pT0), associations with overall survival, and factors influencing downstaging such as neoadjuvant chemotherapy and tumor pathology type.